Men with benign prostatic hyperplasia (BPH) will soon have a therapeutic option that uses a unique drug delivery system. The FDA recently approved alfuzosin (UroXatral, Sanofi-Synthelabo) extended-release tablets for the treatment of the signs and symptoms of BPH. Alfuzosin is not indicated for the treatment of hypertension. The manufacturer expects alfuzosin to be available in pharmacies sometime in the second half of 2003.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
November 21st 2024“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.